PRL-1 is a particularly interesting immediate-early gene because it is induced in mitogen-stimulated cells and regenerating liver but is constitutively expressed in insulin-treated rat H35 hepatoma cells, which otherwise show normal regulation of immediate-early genes. PRL-1 is expressed throughout the course of hepatic regeneration, and its expression is elevated in a number of tumor cell lines. Sequence analysis reveals that PRL-1 encodes a 20-kDa protein with an eight-amino-acid consensus protein tyrosine phosphatase (PTPase) active site. PRL-1 is able to dephosphorylate phosphotyrosine substrates, and mutation of the active-site cysteine residue abolishes this activity. As PRL-1 has no homology to other PTPases outside the active site, it is a new type of PTPase. PRL-1 is located primarily in the cell nucleus. Stably transfected cells which overexpress PRL-1 demonstrate altered cellular growth and morphology and a transformed phenotype.
The liver constitutes one of the few normally quiescent tissues in the adult body that have the capacity to regenerate (3, 10, 33) . As a result, it provides a unique multicellular, physiologically normal system in which to study the mitogenic response of epithelial cells. In the rat, following a 70% hepatectomy, the cells in the remaining, intact, liver lobes rapidly resume proliferation. They initiate the first round of DNA synthesis within 12 to 16 h postsurgery and continue to traverse the cell cycle until the liver regains its initial mass in about 10 days, whereupon the cells again become quiescent. Although it is composed mainly of hepatocytes, the liver has a complex multicellular architecture, implying that intercellular communications must exist during regeneration. Multiple factors, including circulating hormones, growth factors, and nervous input, participate in the regulation of this response, but the actual mechanism remains incompletely understood.
Immediate-early genes, which are induced by mitogens in the absence of de novo protein synthesis, encode proteins which play an important role in the regulation of cell growth (2, 19, 29, 36, 55) . They include proteins of diverse functions (transcription factors and growth factors, etc.), and it is clear that during the growth response, multiple pathways must be simultaneously activated. The mRNA and protein levels of many of these genes remains elevated for extended periods during cell growth, and their regulatory role extends beyond the immediate Go/Gl transition. At the cellular level, proteins encoded by immediate-early genes may help control progression through G, and later phases of the cell cycle. To begin to understand the control of liver regeneration, we identified immediate-early growth response genes in regenerating liver and insulin-treated H35 cells, a minimal-deviation hepatoma cell line that has many properties of regenerating liver. H35 cells become quiescent under serum deprivation and reenter the cell cycle in response to physiologic concentrations of t Present address: Synaptic Pharmaceuticals, Paramus, NJ 07652. insulin (50) . In the two liver systems, 70 total and 41 novel immediate-early genes were identified (36) . Although the majority of the immediate-early genes are common to both liver systems, one gene, PRL-1 (referred to as SL-314 in reference 36) , was of particular interest, because it is induced as an immediate-early gene in regenerating liver and mitogentreated fibroblasts but constitutively expressed in H35 cells.
Upon analysis of the sequence of PRL-1, we noted that it has the signature sequence for a protein tyrosine phosphatase (PTPase) (5, 11, 24, 42, 52) . This was of significance because control of phosphorylation of cellular proteins plays a critical role in cell growth (4) . It is known that a variety of tyrosine kinases, including transmembrane receptors such as the epidermal growth factor and insulin receptors, membrane-associated kinases of the Src family, and more recently tyrosinethreonine kinases like mitogen-activated protein (MAP) kinase kinase, have specific intracellular substrates in the signal transduction pathways that regulate cell growth and metabolism. Initially, it was felt that PTPases played housekeeping roles, but it is now known that they have specific intracellular targets and function in cellular growth control (5, 11, 24, 42, 52) . Although H35 cells have many liver-like properties, they are tumorigenic. We wondered if PRL-1 is important for normal cell growth and if PRL-1 overexpression in H35 cells could contribute to their tumorigenicity. Here we demonstrate that PRL-1 is a PTPase and that it is highly expressed in growing hepatic cells and some tumor cell lines. PRL-1 is located primarily in the cell nucleus, and its overexpression modulates the growth of cells.
MATERIALS AND METHODS
Cell culture and animals. H35 cells were grown as described previously (50) . Following serum deprivation, cells were treated with various agents (insulin [10-8 M; Sigma], fetal bovine serum [FBS; 20%], and cycloheximide [10 ,ug/ml; Sigma]) as described previously (51) . BALB/3T3 cells were grown and induced as described previously (36) . Cells PRL-1 is an immediate-early gene in regenerating liver and serum-stimulated fibroblasts but is constitutively expressed in H35 cells. (A) Northern blot showing expression of PRL-1 mRNA before and 3 h after the application of a mitogenic stimulus in H35 cells (insulin), regenerating liver (RL) (70% hepatectomy), and BALB/ c3T3 (3T3) fibroblasts (serum) in the presence of cycloheximide pretreatment. SFM, serum-free medium; 3CI, 3 h after insulin treatment of serum-starved H35 cells; Q, quiescent liver; 3CH, 3 h after hepatectomy; SD, serum-deprived 3T3 cells; 3CS, 3 h after serum treatment of quiescent 3T3 cells. Sizes are shown in kilobases. (B) Time course of expression of PRL-J in H35 cells before and at various time points before and after the addition of insulin to serum-starved quiescent cells. The ethidium-stained 28S rRNA subunit from the gel is shown for normalization. (C) Time course of expression of PRL-1 in regenerating liver at various time points before and after a 70% hepatectomy. The ethidium-stained 28S rRNA subunit from the gel is shown for normalization. RNA was prepared as described previously (43) . For regenerating liver, Fischer rats (160 to 200 g; Bantin-Kingman) were ether anesthetized and subjected to midventral laparotomy with approximately 70% liver resection (left lateral and median lobes) (20) . For cycloheximide-treated samples, rats were treated with cycloheximide (50 mg/kg; 5% solution in phosphate-buffered saline [PBS]) intraperitoneally 15 min prior to surgery as described elsewhere (2) . Northern (RNA) and Southern blots. RNA preparation, Northern blot analyses, and labeling of recombinant PRL-1 plasmids have been described elsewhere (36) . Hybridization buffer consisted of 10% dextran sulfate, 40% formamide, 0.6 M NaCl, 0.06 M sodium citrate, 7 mM Tris (pH 7.6), 0.8x Denhardt's solution, and 0.002% heat-denatured, sonicated salmon sperm DNA. Northern blots were hybridized at 42°C for 16 h and washed twice for 30 min each time at 60°C in 0.015 M NaCl-0.0015 M sodium citrate-0.1% sodium dodecyl sulfate (SDS) prior to exposure to film (43) . Genomic DNA was extracted from normal rat liver, H35 cells, and human HeLa cells (43) , and Southern transfers were performed. Genomic Tissues were from normal rats, and all cell lines were actively proliferating.
blots were washed twice for 30 min each time at 60°C in 0.0075 M NaCl-0.00075 M sodium citrate-0.1% SDS prior to exposure to film. Purification of bacterially expressed PRL-1 and phosphatase assays. A 543-bp insert encompassing the entire PRL-1 open reading frame was amplified by PCR, and the insert flanked by XhoI-BamHI sites was ligated into the PET vector (39) and then transformed into BL-21 cells. Log-phase cultures were induced for 2 h with 1 mM isopropylthiogalactopyranoside (IPTG), and the cells were pelleted and resuspended in a total volume of 10 ml of 50 mM Tris (pH 7.6)-100 mM NaCl. The cells were then lysed by gentle sonication, and the soluble fraction was collected after the insoluble material was pelleted. The protein was purified by using a nickelagarose column (Qiagen) and nondenaturing conditions as described previously (21) . The purity of the protein was confirmed by running a sample on an SDS-polyacrylamide gel and staining with Coomassie blue. Protein concentrations were determined by the Lowry method. For phosphatase assays, equal volumes of corresponding column fractions were used for both PRL-1 and control proteins. In some cases, the concentration of the control protein in the equivalent volume was less than that for PRL-1. In such cases, appropriate amounts of bovine serum albumin (Sigma) were added so that controls consisted of the same total amount of protein in the same volume of the same column fraction as was used in the PRL-1 assay. The mutant protein was created by using a mutant oligonucleotide (GCTGTCCATTCTGTCGCAGGC CTTGGCAGA) in a PCR. The sequences of the wild-type and mutant plasmids were confirmed.
Transient transfections. Ten micrograms of pCMV-1-PRL-1 (open reading frame of PRL-1 cloned into a pCMV vector by PCR, with sequence confirmed) and control pCMV were transfected into NIH 3T3 cells as we have described previously (22) , and at 48 h after removal of coverslips for immunofluorescence (see below), total cell lysates were prepared (Fig. 4A ). The cells were serum deprived 24 h prior to harvesting. Transfection efficiency was assessed relative to a ,-galactosidase control plasmid. Immunoblots were prepared and analyzed with anti-PRL-1 antibodies by the enhanced chemiluminescence (Amersham) technique as described below. The same VOL. 14, 1994 FIG. 2. (A) Sequence of the PRL-1 cDNA. The amino acid sequence comprising the PTPase active site consensus sequence is shown in boldface, the basic region is underlined, and the potential tyrosine phosphorylation sites are shown in boldface italic. A full-length cDNA was obtained from the regenerating liver cDNA library (36) . The sequence of the clone was determined by the Sanger dideoxy sequencing method (44) and was confirmed through bidirectional sequencing. (B) Alignment of PRL-1 amino acid sequence with sequences of the active sites of the three known classes of PTPases (5, 11, 13-15, 24, 34, 42, 52) . hPTP, human PTPase; VVH1, vaccinia virus H1; Hscdc25, human sequence for cdc25. (C) Genomic Southern blot hybridized with the full-length PRL-1 cDNA probe. transfected NIH 3T3 cells grown on glass coverslips were stained with anti-PRL-1 antibodies for immunofluorescence.
Antibodies, immunofluorescence, and immunoblots. Polyclonal anti-PRL-1 antibodies were prepared by Cocalico Biologicals, Reamstown, Pa., against bacterially expressed purified denatured PRL-1 protein described in the legend to Fig. 3 . Immunoblotting was performed as we have described previously (51), using a 1:1,000 dilution of anti-PRL-1 (ot-PRL-1) antisera followed by a 1:10,000 dilution of goat anti-rabbit sera and the chemiluminescence detection system (Amersham). Immunofluorescence was performed essentially as described elsewhere (18) . Cells were grown to 80% confluence on glass coverslips and serum deprived for 2 days in 1% FBS-Dulbecco modified Eagle medium ( Fig. 4B and 6) or treated as described above for transient transfections. All coverslips were washed with PBS, fixed and permeabilized with 50% methanol-50% acetone, and then treated with affinity-purified anti-PRL-1 antibodies at 4 ng/pl, preimmune sera, or anti-PRL-1-depleted (a-PRL-1-depleted) antisera at an equivalent immunoglobulin concentration (dilutions were made with PBS-5% fetal calf serum-0.01% sodium azide). ot-PRL-1-depleted antisera was prepared from the flowthrough of the PRL-1 affinity column and contained very low residual anti-bacterial PRL-1 activity. Following incubation, cells were rinsed in PBS and antibody buffer and covered for 30 min with rhodamine-conjugated goat anti-rabbit immunoglobulin G diluted 1:100 in antibody buffer. Coverslips were rinsed in PBS, dried, and mounted on glass slides, using 50% PBS-50% glycerol-0.25% phenylenediamine dihydrochloride. Fluorescence was examined in a Nikon Microphot-FXA fluorescence microscope.
Cell extracts. For cellular extracts (Fig. 5 ), growing cells were treated as described previously (54) by sonication in low-salt buffer to prepare the soluble fraction, resuspension of the 100,000 x g pellet in 1% Triton to prepare the Tritonsoluble fraction, and resuspension of Triton-insoluble material in loading dye containing 4% SDS and 10% P-mercaptoethanol. Liver was extracted and fractionated as described previously (27, 51) . Nucleus preparation was verified by microscopy, as we have done previously (22, 51) , and was 99% pure. 37°C for 60 min. The reaction was stopped by the addition of 6 ,ul of 10 N NaOH, and A410 was measured. PRL-1 protein and control protein IKBa (51) were expressed as fusion proteins linked to six histidines in E. coli, using the PET system (39) . (D) Hydrolysis of tyrosine-phosphorylated PRL-1 by PRL-1. c-Src isolated by immunoprecipitation from platelets (23) was added to 2.5 ,ug of inactive PRL-1 (no 3-mercaptoethanol) and 20 ,uCi of [y-32P]ATP in 30 p.l of kinase buffer at room temperature for 15 min (23), after which the reaction was stopped by the addition of EDTA (12 mM). The reaction was then split into equal samples. Tube 1 served as the control; 15 plI of 2x phosphatase buffer (200 mM Tris [pH 7.6], 0.2 M 3-mercaptoethanol) and 2.5 ,ug of active PRL-1 were added to tube 2 (+Active PRL-1), and 3.10 mM sodium orthovanadate was added to tube 3 (+PRL-1/Vanadate). The tubes were then incubated at 37°C for 1 h, and reactions were stopped by the addition of 30 pul of loading dye. Samples containing labeled Src were incubated with phosphatase buffer and control bacterial protein and showed no dephosphorylation. Samples were fractionated on an SDS-polyacrylamide gel, which was then dried and exposed to X-ray film. The results shown are averages of three separate experiments and based on the level of 32P in the Src and PRL-1 phosphoproteins as determined by densitometry. (E) The relative activities of control (IKBa) protein, PRL-1 mutant protein C104S, and wild-type PRL-1 (215 ,ug of each protein per ml) were measured by using the PNPP assay as for panel A. In this experiment, the protein was stored at -20°C in a modified storage buffer containing 20 mM Tris (pH 7.9), 100 mM KCl, 5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 80 mM imidazole, 50% glycerol, 2.5 mM EDTA, and 200 ,ug of acetylated bovine serum albumin per ml.
Cytoplasmic material was further fractionated by a high-speed (100,000 x g) spin, followed by resuspension of the pellet in 0.5% Triton and resuspension of the final Triton-insoluble pellet in loading buffer. Nuclear material was further fractionated by treatment in 0.5% Triton to remove the outer nuclear membrane from intact nuclei, lysis of nuclei by Dounce homogenization, and recovery of nuclear extract. The nuclear extract was subjected to high-speed centrifugation, the pellet was resuspended in 0.5% Triton to recover the Triton-soluble fraction, the Triton-insoluble pellet was resuspended in 1.5 M KCl to recover the salt-extractable material, and the remaining insoluble material was resuspended in loading buffer. The nuclear pellet and KCl fraction represented about 3% of the total cellular protein.
Stable pCMV-PRL-1 cell lines. pCMV-PRL-1 and pCMV stable transfectants were made with 10 ,ug of DNA plus 1 ,ug of neomycin control plasmid, using standard methods (54) . The transfection efficiencies for pCMV control and pCMV-PRL-1 were 10-3 and 10-4, respectively, and approximately 750 total pCMV Neo+ and 75 pCMV-PRL-1 Neo+ clones were obtained in two separate transfection experiments. Specific pCMV-PRL-1 clones were selected for further study on the basis of detecting a relatively high level of PRL-1 protein by immunofluorescence of very early colonies. Immunofluorescence was performed simultaneously in all cell lines with identical reagents, exactly as described for Fig. 6 . For confluence studies, cells were grown in Dulbecco modified Eagle medium-10% FBS to confluence, and the number of cells was determined. Cells were fed regularly and allowed to grow postconfluence. Soft agar cloning was performed as described previously (54) 3T3; pCMV(AD6)] and positive (v-Src-transformed 3T3) control cells. Nucleotide sequence accession number. The GenBank accession number for the sequence shown in Fig. 2A is L27843.
RESULTS
Identification of PRL-1. As with many immediate-early genes, PRL-1 mRNA is generally induced in mitogen-treated cells, including regenerating liver following partial hepatectomy and 3T3 cell fibroblasts following serum stimulation (Fig.  1 ). PRL-1 is an immediate-early gene, as indicated by its induction in the presence of a cycloheximide-mediated protein synthesis blockade (Fig. 1A) . In H35 rat hepatoma cells, however, PRL-1 is constitutively expressed. Even under serumstarved quiescent conditions, PRL-1 is expressed in H35 cells at a level comparable to that seen at various time points after the addition of insulin (Fig. iB) , and there is no PRL-1 superinduction with cycloheximide pretreatment (Fig. 1A) . Unlike expression of some immediate-early genes, PRL-1 expression is not limited to the GI phase of the cell cycle, as PRL-1 mRNA remains elevated throughout the growth response (up to 72 h posthepatectomy) (Fig. 1C ). PRL-1 expression is elevated in both parenchymal and nonparenchymal cells in the regenerating liver (17) , and it is expressed throughout the course of hepatic development (unpublished data). PRL-1 is expressed in brain and skeletal muscle but not in a number of other tissues. High levels of PRL-1 mRNA are also found in several tumor cell lines, but the level of this mRNA is relatively low in proliferating, nontumorigenic cells (e.g., fibroblasts and lymphoblasts) ( Table 1 ).
The full-length PRL-1 cDNA clone corresponds in size to the 2.7-kb mRNA (Fig. 1A ) and contains an additional polyadenylation signal at position 2269 ( Fig. 2A) . This more 5' polyadenylation signal accounts for the 2.5-kb mRNA and was used in one of the cDNA clones that we isolated. The 519-bp open reading frame encodes a 173-amino-acid protein with a projected molecular mass of 19.8 kDa. The open reading frame is flanked by a 546-bp 5' untranslated region and a 1.8-kb 3' untranslated region that contains several ATlTA sequences which could decrease mRNA stability (45) . We confirmed that the long 5' untranslated region is part of the PRL-1 mRNA by using a probe from this region in a Northern blot analysis (not shown). There are multiple stop codons in each frame both before and after the open reading frame. The initial start codon is in a good Kozak consensus sequence site, with both an A at position -3 and a G at position +4 (26) . Presumably because of the long 5' untranslated region, synthetic PRL-1 mRNA translates weakly but detectably in rabbit reticulocyte lysate, migrating as a 20-kDa protein (not shown).
While PRL-1 is a novel gene, we noted that the deduced amino acid sequence contains the VHCXAGXXR signature sequence for the active site of PTPases (Fig. 2B) (5, 11, 24, 42, 52) . The carboxyl terminus of PRL-1 contains a few amino acids, including Val-130, Arg-134, Gln-145, and Leu-146, that are found at similar positions in other classes of PTPases. The balance of the amino acid sequence does not have homology to any previously described PTPases, including 3CH134 (6) (RL-30 in our regenerating liver study [36] ), a VH1 homolog that is also induced in the growth response. PRL-1 is a basic protein (pl 9.53) with a highly basic region toward the carboxyl terminus. It has two potential tyrosine phosphorylation sites near the amino terminus of the protein ( Fig. 2A) and weak consensus sites for protein kinase C and casein kinase II. Hybridization of a PRL-1 probe to genomic Southern blots reveals the presence of multiple bands, even after washing under stringent conditions at high temperature (Fig. 2C ). These bands are highly conserved between rat, H35 cell, and human (HeLa cell) DNAs. Both full-length and coding-region PRL-1 probes hybridize to multiple genomic fragments, suggesting that PRL-1 is a member of a new gene family and/or hybridizes to multiple pseudogenes.
Demonstration of PRL-1's PTPase activity. To demonstrate PRL-l's PTPase activity, we expressed the protein as a histidine fusion protein in Escherichia coli, purified it over a nickel chelate affinity column, and used it in a p-nitrophenyl phosphate (PNPP) assay (8, 15) . We found that PRL-1 has low but definite activity in this system (Fig. 3A) compared with a control recombinant protein isolated from the corresponding fraction from an affinity column. Phosphatase activity is linear with respect to enzyme concentration (Fig. 3A) substrate is varied (Fig. 3C) , with a predicted Vm,, of 2.2 nm/min/mg under these conditions. This activity is lower than those of other PTPases and could be accounted for by improper folding of the bacterial protein or absence of an important regulatory subunit. We also found that a reducing agent such as dithiothreitol or ,-mercaptoethanol is required for PRL-1 phosphatase activity (data not shown), the enzyme activity is heat sensitive, and the pH optimum is 7.3 to 7.5. PRL-1 activity is inhibited by sodium orthovanadate (60% at 1 mM). Unlike the control phosphatase (potato acid phosphatase), PRL-1 was unable to remove phosphate residues from a serine-threonine-phosphorylated substrate (casein) (not shown). Because we found tyrosine phosphorylation sites in PRL-1, we tested whether immunoprecipitated Src could phosphorylate inactive PRL-1 and found that PRL-1 was readily phosphorylated in vitro along with the Src kinase itself. We then arrested the kinase reaction with EDTA and added active PRL-1. In three separate experiments, active PRL-1 dephosphorylated tyrosine-phosphorylated PRL-1 more readily than it dephosphorylated Src (up to 95% versus 40%), and this dephosphorylation was inhibited by orthovanadate ( Fig. 3D ). Other phosphotyrosine substrates that were tested, including cdc2 and angiotensin (8) peptides, were readily dephosphorylated by control phosphatase but not by PRL-1. Finally, to show that the phosphatase activity of PRL-1 is dependent on the cysteine residue present in the active site, we tested the activity of wild-type PRL-1 and C104S PRL-1 in the PNPP assay (Fig. 3E) . As with other PTPases, the phosphatase activity of PRL-1 is completely abolished by the cysteine mutation (16) .
Subcellular localization of PRL-1. To begin to assess the cellular function of PRL-1, we initiated studies to determine its intracellular location. As the normal cellular level of PRL-1 is low and was not readily detectable, we overexpressed PRL-1 in NIH 3T3 cells by using transient transfection. Immunoblotting of serum-deprived pCMV-PRL-1-transfected cells with anti-PRL-1 antibodies revealed a 21-kDa protein not present in control cells (Fig. 4A ). Immunofluorescence of these same cells demonstrated grossly positive cells of slightly abnormal morphology that were not present in transfection controls. Staining was present in both the nucleus and cytoplasm of cells, whereas background cells showed only a small amount of nuclear staining. To further document the integrity of the anti-PRL-1 antibodies and demonstrate subcellular localization of PRL-1 in cells that overexpressed the protein less than transiently transfected cells, we performed further immunofluorescence studies. Immunofluorescence of H35 cells (not shown) or pCMV-PRL-1 stably transfected NIH 3T3 cells with affinity-purified PRL-1 antibodies demonstrated staining in both the nucleus and cytoplasm, but staining was predominantly nuclear (Fig. 4B ). This staining was not detected by preimmune sera or ot-PRL-1-depleted sera (Fig. 4B ).
We used immunoblots to further substantiate the cellular localization of PRL-1. As H35 cells express high levels of PRL-1 mRNA constitutively, we performed immunoblots in growing H35 cells. As we could not detect PRL-1 in total cell extracts, we fractionated the extracts into soluble, membrane, and Triton-insoluble fractions. We clearly detected PRL-1 in the insoluble fraction (Fig. 5, lane 3) , although there was some PRL-1 in the soluble fraction as well in other experiments. PRL-l's presence in the insoluble fraction was surprising since it is readily soluble in E. coli. We reasoned that in cells, PRL-1 must be associated with other proteins that render it insoluble. In the presence of SDS without reducing agents, PRL-1 still migrated at 21 kDa, indicating that these interactions do not depend on disulfide bonds. In the presence of high concentrations of salt (1.5 M KCl), PRL-1 was shifted into the soluble fraction, whereas intermediate filament proteins (vimentin) remained insoluble (not shown), suggesting that interactions between PRL-1 and other proteins can be disrupted. We then performed further nuclear and cytoplasmic fractionation studies in normal and regenerating liver (Fig. 5, lanes 4 to 11) . A 21-kDa protein was detected primarily in the Triton-insoluble nuclear fraction of the regenerating liver. As in H35 cells, PRL-1 was solubilized in high salt.
Effect number of tumor cell lines, we hypothesized that PRL-1 could be a modulator of cell growth. To test this theory, we stably transfected pCMV-PRL-1 and a neomycin gene into NIH 3T3 cells, and scored for Neo+ colonies. Notably, in two separate transfection experiments, we scored only 10% as many pCMV-PRL-1-positive clones (approximately 75 total colonies) as pCMV control clones (approximately 750 total colonies). This finding suggested that very high levels of PRL-1 could be toxic to cells. pCMV-PRL-1 clones were selected for further study on the basis of the high level of PRL-1 protein determined by immunofluorescence of cells during the initial passage. Subsequent studies were performed in early-passage cells. In serumdeprived cells, by immunoblotting (not shown) and immunofluorescence ( Fig. 6 ), PRL-1 levels were threeto fivefold higher in pCMV-PRL-1 cells than in pCMV controls. By immunofluorescence, in all cells, PRL-1 was primarily nuclear and showed a speckled pattern. Both immunofluorescence and immunoblotting produced patterns similar to those for H35 and NIH 3T3 cells, suggesting that in stably transfected cells, PRL-1 compartmentalizes properly. The majority of colonies in the pCMV-PRL-1 transfection grew up rapidly with no delay as compared with control cells. However, a few of the pCMV-PRL-1 colonies contained cells of grossly abnormal morphology, including multinucleated giant cells (Fig. 7A ). Most of these grossly abnormal clones did not propagate sufficiently to be selected. All pCMV-PRL-1 clones that were studied had rapid growth rates (maximum doubling time of approximately 20 h, compared with 24 h for the control) ( Fig. 7B) . Several of the pCMV-PRL-1 lines demonstrated unusual morphology and enhanced saturation density (Fig. 8 ). The number of cells was measured out to 6 days postconfluence to determine saturation density, which was >105/cm2 for all pCMV-PRL-1 cells and 2 x 104/cm2 for pCMV(AD6) (control). The lines that were the most altered morphologically (CD1 and BA1) or had the highest growth rate (BD5) formed colonies in soft agar at a rate comparable to that for v-Srctransfected cells, while BA2 gave greatly increased colonies relative to control cells. v-Src-transfected cells were much more able to form tumors in nude mice than the pCMV-PRL-1 lines that were tested. It is possible that the high level of PRL-1 in the BA2 cells was relatively toxic and contributed to the lower rate of soft agar cloning.
DISCUSSION
Prior to this study, three distinct families of PTPases had been identified, including the large family characterized by PTPa (5, 11, 12, 24, 42, 46, 52) , the vaccinia virus phosphatase family (6, 15, 38) , and the cdc25 family (8, 13, 14, 34) . Among members of each of these families, there is significant homology in regions outside the active site. As judged from its lack of homology to any of these families and the establishment of its enzymatic activity, PRL-1 is a novel type of PTPase. Thus far, PRL-1 shows most activity as an autophosphatase, but its true intracellular substrates are not yet identified. Although studies to date have been negative, it is not clear whether in some instances PRL-1 could have serine-threonine phosphatase activity as well. PRL-1 is a particularly small enzyme, and it is likely that it is associated in the cell with one or more regulatory subunits that could enhance its phosphatase activity. The identification of regulatory subunits and/or specific substrates will be important in delineating its specific activity.
Since it is clear that PTPases and tyrosine kinases play central roles in the regulation of cell growth and division (5, 11, 24, 25, 42, 52) , it is intriguing that we have identified a novel nuclear PTPase induced in the G1 phase of the growth response that alters cell growth. In this regard, we and others have identified members of the vaccinia virus PTPase family that are also induced as part of the growth response in cells and apparently show nuclear localization (6, 38) . Recently, a member of this family has been shown to have a negative effect on cell growth (37) . Other phosphatases have also been shown to modulate cell growth. Some PTPases may actually serve to increase the level of phosphorylation within the cell by dephosphorylating specific regulatory sites on kinases, thus activating them. In this manner, it is possible to envision a significant positive role for PTPases in the growth response. For example, it has been shown that overexpression of PTPat (54), a membrane-associated PTPase, results in cellular transformation through activation of c-Src. Another example of this type of growth enhancement is seen in the cdc2-cdc25 system, in which the cell cycle regulatory kinase cdc2 is specifically activated following dephosphorylation by the PTPase cdc25 (25) . It is known that cdc25 PTPase plays a crucial role in governing the G2-M cell cycle transition in yeast cells and probably in VOL. 14, 1994 3760 DIAMOND ET AL. mammalian cells, in which a number of cdc25 homologs have level of transformation induced by PRL-1 is more modest than been identified (8, 13, 14, 34) .
that seen with v-Src or even PTPot, which appears to act PRL-1, whose expression is elevated in several tumors, is through activation of c-Src. Consistent with this, H35 cells able to alter the growth of 3T3 cells when overexpressed. The which constitutively express PRL-1 also display a relatively low MOL. CELL. BIOL.
PRL-1, A NUCLEAR PROTEIN TYROSINE PHOSPHATASE 3761 level of tumorigenicity and do not grow in the absence of serum. Some pCMV-PRL-1 cells showed grossly abnormal morphology and did not propagate, and immunofluorescence of some of these nascent clones indicated that levels of PRL-1 were high. It appears that very high levels of PRL-1 negatively affect cell growth. However, it is not known what constitutes physiologic levels of PRL-1. It is not clear whether PRL-1 can be a physiologic inhibitor under certain cellular conditions or whether the high levels of PRL-1 achieved in these studies resulted in toxicity due to a loss of substrate specificity. Certain proteins like c-Myc may cause either transformation or cell death under specific physiologic cellular conditions (9) . Unlike other PTPases which are associated with soluble and membrane fractions, the majority of PRL-1 is found in the cell nucleus. However, PRL-1 itself is a small soluble protein that could diffuse through nuclear pores, and it is not surprising that PRL-1 can distribute between nuclear and cytoplasmic fractions, particularly when highly overexpressed. Interestingly, like PRL-1, two proteins involved in cell growth, PP1, a serine-threonine phosphatase, and RB, a protein regulated by serine-threonine phosphorylation, are associated in part with insoluble portions of the cell nucleus such as chromatin or the nuclear envelope. The association of RB with insoluble proteins may be regulated during the cell cycle (1, 27, 35) .
The identification of PRL-l's potential substrates will be of importance in defining its cellular function. At this time, there are three known classes of nuclear tyrosine-phosphorylated proteins that are important in cell growth: MAP kinases (4, 30) , cdc2 family proteins (32) , and some transcription factors (28, 40, 41, (47) (48) (49) . The activity of these tyrosine-phosphorylated proteins may be precisely regulated by specific PTPases that are themselves nuclear. MAP kinase is activated by both threonine and tyrosine phosphorylation and can then move to the cell nucleus, where it phosphorylates substrates such as specific transcription factors and histone H3, thereby modulating their activity. Recently, it has been shown that a nuclear PTPase in the vaccinia virus family can efficiently dephosphorylate MAP kinase, resulting in its inactivation (7, 53) . It is now clear that there are several cdc2-like molecules (cdks) that are also regulated by tyrosine phosphorylation (32) . Some cdks and members of the cyclin family are expressed specifically in the GI phase of the mammalian cell cycle and thus may be important in controlling transition through GI (31) . Although current evidence suggests that cdc2 family proteins are regulated by cdc25-type PTPases, other PTPases could be involved in their regulation as well. Finally, following stimulation with either interferons, cytokines, or growth factors, the transcription factor ISGF-3 (Stat-91) becomes phosphorylated on a tyrosine residue and translocates to the nucleus, where it is able to bind to and regulate target promoters (28, 40, 41, (47) (48) (49) . Linkage of PRL-1's activity to any of these nuclear tyrosine-phosphorylated proteins or other as yet unknown potential substrates will be important in elucidating PRL-1's role in cellular growth control.
